Shawnte Mitchell - 28 Feb 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Reporting relationship: CHIEF LEGAL OFFICER
Issuer ticker: OLMA
Reported as of: 28 Feb 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Mar 2025, 16:18:17 UTC
Prior SEC filing: 28 Feb 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Shane Kovacs, Attorney-in-Fact

Key filing fact

Shawnte Mitchell filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 03 Mar 2025.

Key facts

This page summarizes Shawnte Mitchell's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2025, 16:18.

Change

Previous filing in this sequence was filed on 28 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OLMA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +450,000
Change %
Price: $0.000000
Shares after: 450,000
Date: 28 Feb 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 450,000
Exercise price: $4.37
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option vest on February 28, 2026 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.